ATRA ATARA BIOTHERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ATARA BIOTHERAPEUTICS INC reported revenue of $630K (down 96.4% from a year earlier), net income of −$4.83M and diluted EPS of −$0.32; over the last four quarters revenue was $6.19M and net income −$16.7M; for the fiscal year ended December 2025 revenue was $121M, down 6.3% on the year before.
ATRA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $121M, gross profit n/a, operating income $35.9M, net income $32.7M (margin 27.1%), EPS $2.57
- Fiscal year ended Dec 2024: revenue $129M, gross profit n/a, operating income −$83.4M, net income −$85.4M (margin -66.2%), EPS −$11.41
- Fiscal year ended Dec 2023: revenue $8.57M, gross profit n/a, operating income −$276M, net income −$276M (margin -3220.9%), EPS −$65.19
- Fiscal year ended Dec 2022: revenue $63.6M, gross profit n/a, operating income −$281M, net income −$228M (margin -359.1%), EPS −$2.24
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$340M, net income −$340M (margin n/a), EPS −$3.63
ATRA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $630K (down 96.4% year over year), net income −$4.83M, EPS −$0.32
- Quarter ended Mar 31, 2026: revenue $516K (down 99.5% year over year), net income −$4.15M, EPS −$0.29
- Quarter ended Dec 31, 2025 (from the annual report): revenue $1.60M (down 95.1% year over year), net income −$3.41M, EPS −$0.80
- Quarter ended Sep 30, 2025: revenue $3.45M (down 91.4% year over year), net income −$4.30M, EPS −$0.32
- Quarter ended Jun 30, 2025: revenue $17.6M (down 38.6% year over year), net income $2.39M, EPS $0.19
- Quarter ended Mar 31, 2025: revenue $98.1M (up 258.8% year over year), net income $38.0M, EPS $3.50
- Quarter ended Dec 31, 2024 (from the annual report): revenue $32.8M (up 670.3% year over year), net income −$12.7M, EPS $0.27
- Quarter ended Sep 30, 2024: revenue $40.2M (up 1779.8% year over year), net income −$21.9M, EPS −$2.93
- Quarter ended Jun 30, 2024: revenue $28.6M (up 2892.7% year over year), net income −$19.0M, EPS −$3.10
- Quarter ended Mar 31, 2024: revenue $27.4M (up 2131.4% year over year), net income −$31.8M, EPS −$5.65
- Quarter ended Dec 31, 2023 (from the annual report): revenue $4.25M (up 1824.0% year over year), net income −$60.5M, EPS −$31.16
- Quarter ended Sep 30, 2023: revenue $2.14M (down 52.1% year over year), net income −$69.8M, EPS −$16.40
- Quarter ended Jun 30, 2023: revenue $957K (down 98.1% year over year), net income −$71.1M, EPS −$16.91
- Quarter ended Mar 31, 2023: revenue $1.23M (down 83.2% year over year), net income −$74.8M, EPS −$0.72
- Quarter ended Dec 31, 2022 (from the annual report): revenue $221K, net income −$74.6M, EPS −$0.73
- Quarter ended Sep 30, 2022: revenue $4.46M, net income −$84.1M, EPS −$0.82
- Quarter ended Jun 30, 2022: revenue $51.6M, net income $18.5M, EPS $0.18
- Quarter ended Mar 31, 2022: revenue $7.31M, net income −$88.1M, EPS −$0.87
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$93.3M, EPS −$0.96
- Quarter ended Sep 30, 2021: revenue n/a, net income −$84.7M, EPS −$0.90
ATRA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$50.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$68.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$193M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$270M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$221M, share buybacks n/a
ATRA balance sheet
- Jun 30, 2026: cash $3.22M, total assets $21.0M, total liabilities $58.0M, shareholders' equity −$37.0M
- Mar 31, 2026: cash $8.36M, total assets $20.0M, total liabilities $57.3M, shareholders' equity −$37.3M
- Dec 31, 2025: cash $8.48M, total assets $20.2M, total liabilities $58.7M, shareholders' equity −$38.5M
- Sep 30, 2025: cash $5.74M, total assets $30.2M, total liabilities $66.8M, shareholders' equity −$36.6M
- Jun 30, 2025: cash $16.9M, total assets $36.9M, total liabilities $71.9M, shareholders' equity −$35.0M
- Mar 31, 2025: cash $13.8M, total assets $62.0M, total liabilities $117M, shareholders' equity −$55.1M
- Dec 31, 2024: cash $25.0M, total assets $109M, total liabilities $206M, shareholders' equity −$97.3M
- Sep 30, 2024: cash $46.5M, total assets $143M, total liabilities $233M, shareholders' equity −$90.5M
What is ATRA's revenue?
ATARA BIOTHERAPEUTICS INC reported $6.19M of revenue over its last four quarters, through June 30, 2026.
Is ATRA profitable?
No. ATARA BIOTHERAPEUTICS INC lost $16.7M over the last four quarters.
What is ATRA's EPS?
Diluted earnings per share over the last four quarters were −$1.73; −$0.32 in the latest quarter.